These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28000865)

  • 1. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells.
    Wang Y; Kuramitsu Y; Baron B; Kitagawa T; Tokuda K; Akada J; Maehara SI; Maehara Y; Nakamura K
    Int J Oncol; 2017 Feb; 50(2):606-612. PubMed ID: 28000865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
    Ng SSW ; Tsao MS; Chow S; Hedley DW
    Cancer Res; 2000 Oct; 60(19):5451-5. PubMed ID: 11034087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of phosphatidylinositol 3-kinase/Akt pathway in gemcitabine-induced apoptosis-like cell death in insulinoma cell line INS-1.
    Motoshige H; Oyama K; Takahashi K; Sakurai K
    Biol Pharm Bull; 2012; 35(11):1932-40. PubMed ID: 23123465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
    Cui J; Guo Y; Wu H; Xiong J; Peng T
    Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
    Zhou HY; Yao XM; Chen XD; Tang JM; Qiao ZG; Wu XY
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10283-10289. PubMed ID: 31841183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis.
    Redlak MJ; Miller TA
    Dig Dis Sci; 2011 Feb; 56(2):323-9. PubMed ID: 20585984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of phosphoinositide 3-kinase, LY294002 and wortmannin, affect sperm capacitation and associated phosphorylation of proteins differently: Ca2+-dependent divergences.
    Nauc V; De Lamirande E; Leclerc P; Gagnon C
    J Androl; 2004; 25(4):573-85. PubMed ID: 15223846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K; Fidler IJ
    Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
    Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.
    Bondar VM; Sweeney-Gotsch B; Andreeff M; Mills GB; McConkey DJ
    Mol Cancer Ther; 2002 Oct; 1(12):989-97. PubMed ID: 12481421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.
    Ng SS; Tsao MS; Nicklee T; Hedley DW
    Clin Cancer Res; 2001 Oct; 7(10):3269-75. PubMed ID: 11595724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
    Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H
    Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
    Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
    Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
    Ng SS; Tsao MS; Nicklee T; Hedley DW
    Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth factor-stimulated phosphorylation of Akt and p70(S6K) is differentially inhibited by LY294002 and Wortmannin.
    Adi S; Wu NY; Rosenthal SM
    Endocrinology; 2001 Jan; 142(1):498-501. PubMed ID: 11145615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of phosphatidylinositol-3 kinase/AKT/PKCzeta/lambda pathway in the effect of palmitate on glucose-induced insulin secretion.
    Nogueira TC; Anhê GF; Carvalho CR; Curi R; Bordin S; Carpinelli AR
    Pancreas; 2008 Oct; 37(3):309-15. PubMed ID: 18815554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
    Xu J; Liu S; Yang X; Cao S; Zhou Y
    Life Sci; 2020 Dec; 263():118523. PubMed ID: 33039386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-κB Pathway.
    Liu J; Huang Y; Liu Y; Chen Y
    Med Sci Monit; 2019 Aug; 25():6085-6096. PubMed ID: 31412018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.